Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes
Sandrine Levet, … , Jean-Louis Touraine, Hervé Perron
Sandrine Levet, … , Jean-Louis Touraine, Hervé Perron
Published September 7, 2017
Citation Information: JCI Insight. 2017;2(17):e94387. https://doi.org/10.1172/jci.insight.94387.
View: Text | PDF
Research Article Endocrinology

An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes

  • Text
  • PDF
Abstract

Human endogenous retroviruses (HERVs), remnants of ancestral viral genomic insertions, are known to represent 8% of the human genome and are associated with several pathologies. In particular, the envelope protein of HERV-W family (HERV-W-Env) has been involved in multiple sclerosis pathogenesis. Investigations to detect HERV-W-Env in a few other autoimmune diseases were negative, except in type-1 diabetes (T1D). In patients suffering from T1D, HERV-W-Env protein was detected in 70% of sera, and its corresponding RNA was detected in 57% of peripheral blood mononuclear cells. While studies on human Langerhans islets evidenced the inhibition of insulin secretion by HERV-W-Env, this endogenous protein was found to be expressed by acinar cells in 75% of human T1D pancreata. An extensive immunohistological analysis further revealed a significant correlation between HERV-W-Env expression and macrophage infiltrates in the exocrine part of human pancreata. Such findings were corroborated by in vivo studies on transgenic mice expressing HERV-W-env gene, which displayed hyperglycemia and decreased levels of insulin, along with immune cell infiltrates in their pancreas. Altogether, these results strongly suggest an involvement of HERV-W-Env in T1D pathogenesis. They also provide potentially novel therapeutic perspectives, since unveiling a pathogenic target in T1D.

Authors

Sandrine Levet, Julie Medina, Julie Joanou, Amandine Demolder, Nelly Queruel, Kevin Réant, Matthieu Normand, Marine Seffals, Julie Dimier, Raphaële Germi, Thomas Piofczyk, Jacques Portoukalian, Jean-Louis Touraine, Hervé Perron

×

Figure 2

Characteristics of HERV-W-Env expression in pancreas and during the course of the disease.

Options: View larger image (or click on image) Download as PowerPoint
Characteristics of HERV-W-Env expression in pancreas and during the cour...
(A) Three nPOD T1D cases stained with GN_mAb_Env03 are presented at 0.5× original magnification, and corresponding higher magnification 3× and 10×. nPOD case ID, block number, and pancreas zone are indicated on the left, and disease duration is indicated on the right. Scale bars: 0.5 ×, 5mm; 3×, 500 μm; 10×, 250 μm. (B–D) For each of the 3 cohorts presented in Figure 1, A–C, HERV-W-Env expression is presented as a function of the disease duration, the dotted line representing the positivity cutoff. T1D duration is presented as function of HERV-W-Env protein expression in serum as determined by ELISA (B), as a function of HERV-W-env gene expression in PBMC (C), or as a function of HERV-W-Env expression in pancreas as determined by IHC (D).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts